Understanding how DNA sequences affect immune cell development
Official title: DNA sequence selectivity in conventional and aberrant V(D)J recombination
Funded at University of Oklahoma Hlth Sciences Ctr · NIH-10900637 · Data updated 2026-11-12
This study looks at how certain DNA sequences help immune cells, like B and T cells, create a variety of receptors to fight off infections, while also trying to understand how this process can sometimes go wrong and cause problems, which could help us learn more about the immune system and related diseases.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Oklahoma Hlth Sciences Ctr NIH-funded |
| Lab location | 1 site (Oklahoma City, United States) |
| Project start | August 7, 2023 |
| Project end | July 31, 2027 |
| Funding year | 2024 |
| Award (this year) | $451,311 |
| NIH project number | 5R01AI168175-02 |
| Project ID | NIH-10900637 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals with immune system disorders or those interested in the genetic basis of immune responses.
✕Less likely to help
Patients with non-immune related conditions or those not affected by immune system disorders may not benefit from this research.
What this research studies
This research investigates the process of V(D)J recombination, which is crucial for generating diverse antigen receptors in immune cells. It focuses on how specific DNA sequences influence the efficiency and accuracy of this recombination process, which occurs during the development of B and T cells. By utilizing a high-throughput method to analyze various recombination signal sequences, the study aims to uncover the balance between successful immune receptor formation and the risk of harmful chromosomal rearrangements. This could lead to a better understanding of immune system function and its implications for diseases.
Why it matters
Potential benefit: If successful, this research could enhance our understanding of immune system disorders and lead to improved therapies for related diseases.
How similar studies have gone: Previous research has shown promising results in understanding V(D)J recombination, but this specific approach to analyzing DNA sequence selectivity is relatively novel.
Where this research is happening
-
University of Oklahoma Hlth Sciences Ctr
Oklahoma City, United States Active
Researchers
- Principal investigator: Rodgers, Karla K — University of Oklahoma Hlth Sciences Ctr
- Study coordinator: Rodgers, Karla K
Related research
Other NIH-funded projects on the same topics.
-
Primary care research network in Oklahoma to boost rural patient trials
A nationwide NIH-supported effort to strengthen Oklahoma’s primary care research network so doctors can run big clinical trials and real‑world studies in rural communities.
-
N-myristoylation and DNA damage response in Alzheimer’s disease
A study to understand how a protein modification called myristoylation affects the DNA damage response in people who have Alzheimer’s-related conditions.
-
Genetically engineered mouse model to study and treat high-risk pediatric rhabdomyosarcoma
A research project aims to create mouse models that mimic high-risk pediatric rhabdomyosarcoma and test therapies that target the NOTCH1 pathway to slow or stop tumor growth.
-
Understanding how bone cancer cells rely on certain pathways to grow in childhood osteosarcoma
This grant studies how specific cancer-related pathways in bone-forming cells drive osteosarcoma in children, with the aim of finding better treatments.
-
Vascular signals from brain blood vessels influence immune-suppressing cells in glioblastoma
This grant explores how blood vessel cells in glioblastoma shape immune cells to help the tumor grow, with the aim of making immunotherapies work better for patients.
-
TFEB as a key switch to keep muscles healthy as we age
A study in aging adults and aging muscle tissues looks at whether boosting TFEB can improve how muscles maintain themselves and recover after disuse.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.